Christine Brennan Ph.D.

PartnerMRL Ventures Fund

Dr. Brennan has over 15 years in the life-science industry, including business development, corporate strategy and venture investing.  She is currently a partner at MRL Ventures Fund (MRLV) and responsible for MRLV’s investments in Entrada Therapeutics, Alector (NASDAQ:ALEC) and Translate Bio (NASDAQ:TBIO). Prior to MRLV, she was principal at the Novartis Venture Fund from 2013-2017 and chief business officer at Vitae Pharmaceuticals from 2010-2013. She also held positions in business development and marketing at small biopharmaceutical and large pharmaceutical companies. Dr. Brennan received her Ph.D. in neuroscience from Dartmouth Medical School and did postdoctoral research in developmental neurobiology at the National Institutes of Health.